Terumo strengthens pharmaceutical location in Germany with establishment at CHEMPARK Leverkusen
Advertisement
New location at CHEMPARK: The leading Japanese medical technology group Terumo is coming to CHEMPARK Leverkusen and will manufacture important pharmaceutical products there in future. As a first step, Terumo has taken over the production facility and the associated quality control laboratories from WuXi Biologics. With this investment, Terumo is underlining the attractiveness of CHEMPARK Leverkusen as a location for leading international medical technology and pharmaceutical companies and strengthening Germany's resilience as an industrial location.
The acquisition was successfully completed on September 30, 2025 and marks an important milestone for Terumo: it is the company's first CDMO production site outside Japan. CDMO stands for Contract Development and Manufacturing Organization and means that pharmaceutical and biotechnology companies are offered services in the development and manufacture of drugs - from early product development to clinical trials and commercial production.
The facility covers around 13,000 square meters and will employ around 150 highly qualified specialists. It will provide pharmaceutical development and manufacturing services, including filling and packaging processes for vials and prefilled polymer syringes as well as autoinjector assembly. The site meets the highest industry standards and has state-of-the-art technologies for the manufacture of critical pharmaceutical products.
"Terumo's relocation to the Chempark Leverkusen is a strong signal for Germany as a business location - and for our Chempark. Terumo's relocation increases Germany's resilience in the production of vital pharmaceutical products. It is also a positive growth signal for Germany as a business location as a whole. The move also shows that our diversified growth strategy for new relocations is bearing fruit," says Currenta CEO Tim Hartmann.
Noritsugu Fujita, Division President, Pharmaceutical Solutions Division, Terumo, adds: "Our expanded presence in Europe and our unique CDMO capabilities will help biopharmaceutical companies bring effective treatments for chronic diseases to market more efficiently."
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
